Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study

PURPOSE: The aim of this study was to assess the efficacy and safety of concurrent apatinib and docetaxel therapy vs apatinib monotherapy as third- or subsequent-line treatment for advanced gastric adenocarcinoma (GAC). METHODS: Patients, who had received apatinib with or without docetaxel as third...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Haimin, Han, Dali, Fu, Guobin, Liu, Chengxin, Wang, Lili, Han, Shumei, Liu, Bo, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400117/
https://www.ncbi.nlm.nih.gov/pubmed/30881023
http://dx.doi.org/10.2147/OTT.S193801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400117/
https://www.ncbi.nlm.nih.gov/pubmed/30881023
http://dx.doi.org/10.2147/OTT.S193801

Ejemplares similares